Zhou, Y., Zhang, Y., Guo, G., Cai, X., Yu, H., Cai, Y., . . . Zhang, L. (2020). Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer. Clin Transl Med.

Zhou, Yixin, Yaqiong Zhang, Guifang Guo, Xiuyu Cai, Hui Yu, Yanyu Cai, Bei Zhang, Shaodong Hong, and Li Zhang. "Nivolumab Plus Ipilimumab Versus Pembrolizumab As Chemotherapy‐free, First‐line Treatment for PD‐L1‐positive Non‐small Cell Lung Cancer." Clin Transl Med 2020.

Zhou, Yixin, et al. "Nivolumab Plus Ipilimumab Versus Pembrolizumab As Chemotherapy‐free, First‐line Treatment for PD‐L1‐positive Non‐small Cell Lung Cancer." Clin Transl Med 2020.